Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristen Villar

Nurse Practitioner, Family Baton Rouge, LA Nurse Practitioner

NPI 1790442507 CMS profile 11269757

10101 Park Rowe Ave Ste 200, Baton Rouge, LA 70810

Open in the dashboard

General payments

$17,586

1,035 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristen Villar of Baton Rouge, LA is reported in the CMS Open Payments database as having received $17,586 across 1,035 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,989 214
2024 General $5,971 334
2023 General $4,413 278
2022 General $3,151 206
2021 General $63 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristen Villar
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kristen Villar were reported at $3,989. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kristen Villar Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $63 $124 $35–$379 $132
2022 $3,151 $141 $44–$430 $149
2023 $4,413 $154 $49–$476 $160
2024 $5,971 $165 $51–$504 $164
2025 $3,989 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,406 183 payments
  2. Neurocrine Biosciences, Inc. $2,252 220 payments
  3. Biogen, Inc. $1,199 53 payments
  4. UCB, Inc. $815 41 payments
  5. Pfizer Inc. $786 67 payments
  6. EMD Serono, Inc. $729 24 payments
  7. TG Therapeutics, Inc. $704 32 payments
  8. Teva Pharmaceuticals USA, Inc. $544 22 payments
  9. Alexion Pharmaceuticals, Inc. $478 15 payments
  10. Lilly USA, LLC $468 31 payments
  11. Other $7,204 347 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,882 1,029 payments
  2. Consulting Fee $475 3 payments
  3. Education $229 3 payments
Products named General payments · program years 2021–2025
  1. INGREZZA $2,252 220 payments
  2. QULIPTA $1,104 80 payments
  3. UBRELVY $1,099 92 payments
  4. Ongentys $986 113 payments
  5. BOTOX $824 57 payments
  6. NURTEC ODT $761 65 payments
  7. TYSABRI $725 31 payments
  8. BRIUMVI $704 32 payments
  9. Briviact $683 35 payments
  10. ZAVZPRET $508 45 payments
  11. Other $10,695 535 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 77 drugs

Part D claims

3,028

Median for Nurse Practitioner: 389

Drug cost

$2,484,559

Median for Nurse Practitioner: $21,885

Branded share of claims

28.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kesimpta Pen Ofatumumab Brand 107 $1,000,032
Enspryng Satralizumab-Mwge Brand 16 $283,064
Tecfidera Dimethyl Fumarate Brand 26 $241,162
Copaxone Glatiramer Acetate Brand 24 $145,362
Teriflunomide Generic 39 $117,674
Rebif Interferon Beta-1a/Albumin Brand 12 $117,636
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 14 $102,797
Tysabri Natalizumab Brand 12 $100,457
Dalfampridine Er Dalfampridine Brand 87 $69,656
Nurtec Odt Rimegepant Sulfate Brand 31 $54,451

The 10 drugs with the highest cost, of 77 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$39,954

Medicare's payments for the services billed

Medicare patients

222

Average age 68

Services billed

2,625

163 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Depression 41%
Diabetes 28%
Ischemic heart disease 24%
Chronic kidney disease 20%
Osteoporosis 18%
Alzheimer's or dementia 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 40 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
$693 — —
PURIFIED CORTROPHIN GEL
$409 — —
QULIPTA
$288 45 —
UBRELVY
$272 19 —
BOTOX
$235 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 40 with Patron

Records

1,035 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record